Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: vancomycin-resistant enterococcus faecium: routine outbreak analyses

PROVIDER: PRJNA854814 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19916600_1.fastq.gz	Fastqsanger.gz
	SRR19916600_2.fastq.gz	Fastqsanger.gz
	SRR19916700_1.fastq.gz	Fastqsanger.gz
	SRR19916700_2.fastq.gz	Fastqsanger.gz
	SRR19916800_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 950

Similar Datasets

Project description:Vancomycin Resistant Enterococcus faecium outbreak suspected strain

| PRJNA1049039 | ENA

A comprehensive microarray analysis of Enterococcus faecium in response to vancomycin in combination with the essential oil components carvacrol and cuminaldehyde

Project description:This study aims to determine the global gene expression in vancomycin resistant Enterococcus faecium (VRE) in response to a novel essential oil-vancomycin combination, and the individual components (vancomycin, carvacrol and cuminaldehyde) to help determine the mechanism of action of this antimicrobial formulation. This formulation increases the susceptibility of VRE to vancomycin and the array provides data on the synergistic mechanism of action. Five conditions (1. Control; 2. Carvacrol, 1.98 mM; 3. Cuminaldehyde, 4.20 mM; 4. Vancomycin, 0.031 mg/l; 5. Combination, 1.98 mM Carvacrol, 4.2 mM Cuminaldehyde, 0.031 mg/l vancomycin) all with 1% DMSO were tested in triplicate with a 60 minute exposure time before extraction.

2019-12-31 | E-MTAB-8072 | biostudies-arrayexpress

Project description:Vancomycin-resistant Enterococcus faecium

| PRJNA518133 | ENA

Project description:vancomycin resistant enterococcus faecium

| PRJNA1227402 | ENA

GNPS - vancomycin-resistant Enterococcus faecium strains preliminary

Project description:Preliminary analysis on extracts (pellets and supernatant) of vancomycin-resistant Enterococcus faecium strains cultured in BHI media. Untargeted LC-MS/MS acquisition performed in positive ion mode.

| MSV000092864 | GNPS

Enterococcus faecium

Project description:Linezolid - vancomycin resistant enterococcus faecium

| PRJNA607166 | ENA

Early identification of a nosocomial outbreak of vancomycin-resistant Enterococcus faecium by Fourier-transform infrared spectroscopy and performance comparison with PFGE and WGS

Project description:Early identification of a nosocomial outbreak of vancomycin-resistant Enterococcus faecium

| PRJEB73881 | ENA

Project description:Vancomycin-resistant Enterococcus faecium from outbreaks

| PRJNA477347 | ENA

Enterococcus faecium

Project description:Vancomycin-resistant Enterococcus faecium Genome sequencing

| PRJNA662846 | ENA

Evolutionary collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faecium

Project description:The rise of antibiotic resistance and decline of antibiotic discovery urgently calls for novel mechanistic understanding of pharmacological and evolutionary interactions between antibiotics and multidrug resistant bacteria to revitalize existing antibiotics. The evolutionary cross-resistance to antibiotics has received intensive attention previously. Nevertheless, whether and how bacteria develop negative responses, under the selective pressure of antibiotics by inverting the evolutionary trajectory remains unclear. Here we found an instance of collateral sensitivity, in which clinical vancomycin-resistant Enterococcus faecium (VREfm) pathogens exhibit dramatic and specific susceptibility to pleuromutilin antibiotics, decreased minimal inhibitory concentrations (MICs) from 128 µg/mL to 0.03 µg/mL. The unique trade-off between vancomycin and pleuromutilins is mediated by the epistasis between the van gene cluster and msrC encoding an ABC-F protein protecting bacterial ribosomes. We validated the efficacy of pleuromutilins in vivo through reducing colonization and promoting microbiota restoration. Our findings provide an alternative approach to inverting the selective advantage and reversing the route of vancomycin resistance evolution, and to treat VREfm associated infections.

2022-05-20 | PXD030906 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data